Author:
Singh Parminder,Agarwal Neeraj,Pal Sumanta K.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Reference30 articles.
1. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688–96.
2. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289–96.
3. Pal SK, Kortylewski M, Yu H, Figlin RA. Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers. Mol Cancer Ther. 2010;9:3115–25.
4. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib vs interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24. This study led to approval of sunitinib as first line therapy for clear cell renal cancer.
5. National Comprehensive Cancer Network Clinical Practice Guidelines: Renal Cell Carcinoma. Available at http://www.nccn.org . Accessed 29 Mar 2014. This provides the consensus guidelines of national and international experts for treatment of renal cancer.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献